Bulletin
Investor Alert

New York Markets After Hours

Lipocine Inc.

NAS: LPCN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Aug 11, 2022, 4:01 p.m.

/zigman2/quotes/202742746/composite

$

0.74

Change

+0.04 +4.99%

Volume

Volume 1,253

Quotes are delayed by 20 min

/zigman2/quotes/202742746/composite

Today's close

$ 0.71

$ 0.70

Change

-0.0090 -1.26%

Day low

Day high

$0.70

$0.73

Open

52 week low

52 week high

$0.70

$1.89

Open

Company Description

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The firm is involved in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabo...

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The firm is involved in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT.

Valuation

P/E Ratio (with extraordinary items)

18.74

Price to Sales Ratio

5.34

Price to Book Ratio

1.92

Enterprise Value to EBITDA

6.95

Enterprise Value to Sales

1.31

Efficiency

Total Asset Turnover

0.41

Liquidity

Current Ratio

8.26

Quick Ratio

8.26

Cash Ratio

7.94

Profitability

Gross Margin

100.00

Operating Margin

19.49

Pretax Margin

-3.93

Net Margin

-3.93

Return on Assets

-1.63

Return on Equity

-2.08

Return on Total Capital

9.14

Capital Structure

Total Debt to Total Assets

4.40

Officers and Executives

Name Age Officer Since Title
Dr. Mahesh V. Patel 62 1997 President, Chief Executive Officer & Director
Dr. Anthony DelConte 61 - Chief Medical Director
Dr. Nachiappan Chidambaram - 2014 Vice President
Mr. John W. Higuchi 51 2013 Director
Ms. Krista Fogarty 53 2018 Controller

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/17/2022 Krista Fogarty
Principal Accounting Officer
12,500   Acquisition at $0.86 per share. 10,750
05/16/2022 Mahesh V. Patel
CEO and President; Director
50,000   Acquisition at $0.77 per share. 38,500
11/18/2021 Mahesh V. Patel
CEO and President; Director
25,000   Acquisition at $1.09 per share. 27,250
12/31/2020 John W. Higuchi
Director
5,000   Disposition at $1.35 per share. 6,750
12/31/2020 John W. Higuchi
Director
1,700   Disposition at $1.34 per share. 2,278
12/16/2020 Mahesh V. Patel
CEO and President; Director
15,000   Disposition at $1.35 per share. 20,250
12/16/2020 Morgan R. Brown
EVP and CFO
8,437   Disposition at $1.35 per share. 11,389
12/16/2020 Mahesh V. Patel
CEO and President; Director
45,000   Derivative/Non-derivative trans. at $0 per share. 0
12/16/2020 John W. Higuchi
Director
3,750   Derivative/Non-derivative trans. at $0 per share. 0
12/16/2020 Morgan R. Brown
EVP and CFO
28,125   Derivative/Non-derivative trans. at $0 per share. 0
12/16/2020 Stephen Anthony Hill
Director
7,500   Derivative/Non-derivative trans. at $0 per share. 0
12/16/2020 Richard Dana Ono
Director
5,250   Derivative/Non-derivative trans. at $0 per share. 0
12/16/2020 Jeffrey Arvin Fink
Director
5,625   Derivative/Non-derivative trans. at $0 per share. 0
12/05/2020 Mahesh V. Patel
CEO and President; Director
122,978   Derivative/Non-derivative trans. at $0 per share. 0
12/05/2020 Morgan R. Brown
EVP and CFO
70,754   Derivative/Non-derivative trans. at $0 per share. 0
12/04/2020 Mahesh V. Patel
CEO and President; Director
43,500   Disposition at $1.57 per share. 68,295
12/04/2020 Morgan R. Brown
EVP and CFO
17,250   Disposition at $1.57 per share. 27,082
12/04/2020 Mahesh V. Patel
CEO and President; Director
145,000   Derivative/Non-derivative trans. at $0 per share. 0
12/04/2020 Morgan R. Brown
EVP and CFO
57,500   Derivative/Non-derivative trans. at $0 per share. 0
03/17/2020 John W. Higuchi
Director
220,000   Acquisition at $0.32 per share. 70,400
12/31/2019 Mahesh V. Patel
CEO and President; Director
40,000   Acquisition at $0.38 per share. 15,200
12/10/2019 Mahesh V. Patel
CEO and President; Director
25,000   Acquisition at $0.4 per share. 10,000
/news/latest/company/us/lpcn

MarketWatch News on LPCN

  1. Lipocine shares plummet 35% after FDA fails to approve its testosterone replacement therapy

    7:03 a.m. May 9, 2018

    - Emma Court

  2. Lipocine downgraded to hold from buy at Canaccord

    11:22 a.m. Jan. 11, 2018

    - Tomi Kilgore

  3. Lipocine stock price target cut to $2 from $11 at Canaccord

    11:23 a.m. Jan. 11, 2018

    - Tomi Kilgore

  4. 6 stocks to watch

    3:38 p.m. Sept. 9, 2015

    - The Trading Deck

  5. 4 stocks to watch

    3:21 p.m. Sept. 2, 2015

    - The Trading Deck

  6. Bed Bath & Beyond surges on earnings

    5:39 p.m. Sept. 23, 2014

    - MarketWatch

/news/nonmarketwatch/company/us/lpcn

Other News on LPCN

  1. 10-Q: LIPOCINE INC.

    9:04 a.m. Aug. 8, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  2. 10-Q: LIPOCINE INC.

    8:06 a.m. May 9, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  3. MVIS, MRIN and CLVR among mid-day movers

    12:46 p.m. March 29, 2022

    - Seeking Alpha

  4. 10-K: LIPOCINE INC.

    9:04 a.m. March 9, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  5. 10-Q: LIPOCINE INC.

    9:03 a.m. Nov. 10, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  6. BGVF, VYNT and SNMP among pre market gainers

    8:38 a.m. Nov. 4, 2021

    - Seeking Alpha

  7. Warning: LPCN is at high risk of performing badly

    4:54 a.m. Oct. 27, 2021

    - Seeking Alpha

  8. AG, FRO and WATT among pre market gainers

    8:33 a.m. Oct. 19, 2021

    - Seeking Alpha

  9. FDA affirms class 1 NDA resubmission for Lipocine's Tlando

    8:35 a.m. Sept. 28, 2021

    - Seeking Alpha

  10. Lipocine discloses mid-stage data for NASH candidate

    8:29 a.m. Aug. 25, 2021

    - Seeking Alpha

  11. Loading more headlines...

At a Glance

Lipocine, Inc.

675 Arapeen Drive

Suite 202

Salt Lake City, Utah 84108

Phone

1 8019947383

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$16.14M

Net Income

$-634,399

Employees

13.00

/news/pressrelease/company/us/lpcn

Press Releases on LPCN

  1. FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment

    8:00 a.m. July 11, 2022

    - PR Newswire - PRF

  2. LIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS

    8:00 a.m. June 14, 2022

    - PR Newswire - PRF

  3. Loading more headlines...
Link to MarketWatch's Slice.